EYEGライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Stats
本日の出来高	10 000.00
平均出来高	469.00
時価総額	64.23M
EPS	$-0.420 ( 2021-11-08 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-19.65
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-02	From Stephen	Sell	250	Common Stock
2021-11-02	Mann Brenda	Sell	62	Common Stock
2021-10-04	Mann Brenda	Sell	62	Common Stock
2021-10-04	From Stephen	Sell	249	Common Stock
2021-09-02	From Stephen	Sell	253	Common Stock

INSIDER POWER
0.00
Last 98 transactions
Buy: 1 959 813 \| Sell: 207 057

EyeGate Pharmaceuticals 相関

10 最も正の相関
BMTC	0.948
XPDI	0.926
FATE	0.912
TCDA	0.908
GRAY	0.905
ENPH	0.896
BCAB	0.895
ODT	0.887
HECCU	0.884
LHDX	0.879

10 最も負の相関
TIG	-0.936
CCRC	-0.928
FRGI	-0.917
ARNA	-0.903
DSPG	-0.899
ACIW	-0.899
NTES	-0.896
EXAS	-0.896
APEN	-0.896
GGAL	-0.895

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

EyeGate Pharmaceuticals 財務諸表

Annual	2020
収益:	$12 059.00
総利益:	$12.06 (0.10 %)
EPS:	$-2.54

FY	2020
収益:	$12 059.00
総利益:	$12.06 (0.10 %)
EPS:	$-2.54

FY	2019
収益:	$2.69M
総利益:	$0.00 (0.00 %)
EPS:	$-2.23

FY	2018
収益:	$1.65M
総利益:	$0.00 (0.00 %)
EPS:	$-4.50

Financial Reports:

No articles found.

EyeGate Pharmaceuticals

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.